Comments on Proposed Standards for Privacy of Individually Identifiable Health Information

Feb 15 2000
Addressed to Margaret Ann Hamburg, M.D., Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services.

Testimony of H. Stewart Parker

Feb 2 2000
On behalf of the Biotechnology Industry Organization (BIO), on oversight of gene therapy before the U.S. Senate Health, Education, Labor and Pensions Subcommittee on Public Health.

Comments submitted to Secretary's Advisory Committee on Genetic Testing in response to the public consultation

Jan 31 2000
On Genetic Testing in response to the public consultation.

BIO's statement regarding reform of Hatch-Waxman Law

Jul 1 1999
The Biotechnology Industry Organization (BIO) supports reforms of the Hatch Waxman Act that will provide full day-for-day restoration of lost patent term for drugs which require extended reviews and/or clinical trials for FDA approval.

Statement regarding confidentiality of patient medical records

May 27 1999
Submitted to the Subcommittee on Health and the Environment House Commerce Committee

BIO's testimony on patent reform to maximize innovation in the biotechnology industry

Mar 25 1999
BIO supports amendments to the patent law that, above all, ensure that diligent patent applicants are not penalized for delays which are beyond their control.

BIO Response to NBAC on Stem Cell Research

Mar 22 1999
BIO appreciates the NBAC's leadership in analyzing the potential benefits and the ethical implications of research on stem cells and we thank you for this opportunity to comment.

BIO Statement Regarding Commercial Development of Pluripotent Stem Cells

Jan 12 1999
To the Subcommittee on Labor, Health and Human Services, Education of the Senate Appropriations Committee

Support of Voluntary Moratorium

Mar 27 1997
Letter to President Bill Clinton